Skip to main content
SpringerLink
Log in

Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 03 June 2019

The Original Article was published on 04 April 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox® new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019. https://doi.org/10.1007/s40262-019-00747-3.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Cox C. Delta method. In: Gail MH, Benichou J, editors. Encyclopedia of biostatistics. New York: Wiley; 1998. p. 1125–7.

    Google Scholar 

  3. Les jours. “Levothyrox: une étude confirme le laxisme de Merck et de l’ANSM”. 2019. https://lesjours.fr/obsessions/levothyrox/ep20-etude-laxisme-ansm. Accessed 13 Apr 2019.

  4. Le Monde. “Levothyrox: l’étude qui donne raison aux patients”. 2019. https://www.lemonde.fr/sciences/article/2019/04/04/levothyrox-une-etude-donne-raison-aux-patients_5445668_1650684.html. Accessed 13 Apr 2019.

  5. Politique.org, “Scandale du Levothyrox: l’étude qui donne raison aux patients”. 2019. http://www.politique.org/blog/2019/04/09/scandale-du-levothyrox-letude-qui-donne-raison-aux-patients/. Accessed 13 Apr 2019.

Download references

Author information

Authors and Affiliations

  1. Biostatistics and Epidemiology Unit, Hôpital Cochin, 27 rue du faubourg Saint-Jacques, 75014, Paris, France

    Joël Coste

  2. Paris Descartes School of Medicine, Paris Descartes University, Paris, France

    Joël Coste & Xavier Bertagna

  3. EPI-PHARE (GIS ANSM-CNAM), Paris, Saint-Denis, France

    Mahmoud Zureik

  4. Versailles Saint-Quentin University, Versailles, France

    Mahmoud Zureik

Authors
  1. Joël Coste
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Bertagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahmoud Zureik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joël Coste.

Ethics declarations

Funding

No external funding was used in the preparation of this letter.

Conflict of interest

Joël Coste, Xavier Bertagna, and Mahmoud Zureik have no conflicts of interest that are directly relevant to the content of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Coste, J., Bertagna, X. & Zureik, M. Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”. Clin Pharmacokinet 58, 965–966 (2019). https://doi.org/10.1007/s40262-019-00779-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-019-00779-9

Search

Navigation